提醒成功

搜索
产品规范 | |
---|---|
Type | In Vivo - Reseach Grade Antibody |
Host | CHO cells |
catalog# | B00057 |
Application | Flow cytometry, animal model study |
Aliases | Acylated Glucagon-like Peptide-1 Receptor Agonist, Human GLP-1 Receptor Agonist, Human GLP-1 Analog |
Size/Concentration | 20mg/60mg/180mg |
Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Formulation | PBS, pH 7.4 |
Description |
---|
What is research grade semaglutide biosimilar? Research grade semaglutide biosimilar has the same amino acid sequence as semaglutide, a recombinant peptide which presents 94% sequence homology to the human glucagon-like peptide-1 (GLP-1), differing primarily by two amino-acid substitutions at positions 8 and 34, where alanine and lysine are replaced by 2-aminoisobutyric acid and arginine, respectively. Liraglutide is made by attaching a C-18 fatty acid (stearic diacid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Semaglutide is resistant to the dipeptidylpeptidase-4 enzyme whic degrades the natural hormone. As a GLP-1 receptor agonist, Semaglutide mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control. Semaglutide is an anti-diabetic medication used to treat type 2 diabetes, obesity, and chronic weight management. |
Semaglutide Biosimilar B00057
规格:
- 20mg
- 60mg
- 180mg
数量:
-
+
说明书:


¥2275
-
咨询
-
收藏

